Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07184528

PATCHVALVE: Endobronchial Valves Plus Blood Patch for Persistent Air Leaks

The goal of this study is to evaluate the real-world safety and effectiveness of combining endobronchial valve (IBV) placement with endobronchial blood patching (EBP) for the treatment of persistent air leaks (PALs) in adult patients undergoing bronchoscopy. PALs are a challenging condition often associated with prolonged hospital stays, increased morbidity, and delayed recovery.

The main questions this study aims to answer are:

* Does the combination of endobronchial valve placement and endobronchial blood patching accelerate resolution of persistent air leaks? * What are the procedural outcomes, complications, and hospital-related metrics (e.g., chest tube duration, length of stay, and readmission rates) associated with this technique?

Participants will:

* Undergo standard-of-care bronchoscopy with identification of air leak source. * Receive intrabronchial instillation of autologous blood and tranexamic acid (TXA) followed by balloon occlusion and endobronchial valve placement. * Be followed for resolution of air leak and post-procedure outcomes through standard inpatient monitoring and data collection.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Beth Isreal Deaconess Medical Center

Boston, Massachusetts, 02215, United States

Location status: Recruiting

Location contact

Beth Isreal Deaconess Medical Center

CONTACT

[email protected]

(617) 667-7000

Christine Conley, MD

CONTACT

[email protected]

About this study

This study will include a prospective cohort of adult patients with persistent air leaks (PALs) undergoing bronchoscopy. The intervention evaluated is a combination approach that includes endobronchial valve placement and instillation of autologous blood with tranexamic acid (TXA), followed by balloon occlusion (referred to as "PATCHVALVE" technique).

Patients will be enrolled and undergo standard imaging and procedural evaluations. For prospective participants, informed consent will be obtained prior to the procedure.

Procedural steps include:

  • Identification of the leaking segment using imaging and air leak assessment.
  • Instillation of fresh autologous blood (up to 30 mL) followed by TXA (up to 10 mL) via a balloon catheter into the leaking airway segment.
  • Balloon occlusion for 3-5 minutes to promote clotting and adherence.
  • Deployment of endobronchial valves based on standard criteria.
  • Leak reassessment and iterative treatment if necessary.

This study will provide early evidence on the efficacy of this combined approach and help standardize care protocols for managing PALs non-surgically.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

{Inclusion Criteria}

  • Adult (≥18 years) patients who have been diagnosed with persistent air leaks (PALs) due to conditions such as alveolar-pleural fistulas following pulmonary resections, traumatic injury, or underlying lung disease or other cause.
  • PAL patients who are deemed non-candidates for surgical intervention or have declined surgery.

{Exclusion Criteria}

  • Patients who have received other experimental or investigational treatments for PALs that could confound the results.
  • Patients with contraindications to undergoing bronchoscopy, such as severe cardiovascular instability, or those who cannot tolerate the procedure due to other medical reasons.
  • Bronchopleural fistula

Treatment and study plan

Endobronchial Blood Patch

Device

This component of the procedure involves sealing persistent air leak (PAL) defects using autologous blood delivered via a balloon catheter. After identifying the target segment, carefully noting the airway angle and distal carina, a sizing balloon is deployed and inflated to ensure a tight seal. Under anesthesia, 30 mL of fresh blood is prepared and infused into the target airway until either visible extravasation occurs or the full volume is delivered. Following this, up to 10 mL of tranexamic acid (TXA) may be administered, again until extravasation occurs or the volume is fully instilled. The balloon remains inflated for 3-5 minutes after the instillation to allow clot formation and sealing of the defect.

Spiration Valve System (SVS) Placement

Device

Once the blood patch component is complete and the balloon is deflated, a Spiration Valve System (SVS) is placed proximally in the airway. The valve acts as a one-way device that decompresses the targeted lung segment while stabilizing the clot created by the blood patch. This supports durable resolution of the air leak, particularly in cases where collateral ventilation might otherwise reduce the efficacy of valve therapy alone.

Primary outcomes

  1. Incidence of Adverse Events Following Combined Blood Patch and Spiration Valve Application

    Time frame: From enrollment to the end of the observational period at 12 months post-intervention as per standard procedure

    This outcome will assess the safety of the combined blood patch and Spiration valve intervention by measuring the number of participants who experience one or more adverse events. Adverse events may include valve migration, the emergence of new air leaks in lung lobes other than the treated segment, and deterioration in pulmonary function, such as worsened gas exchange or progression to respiratory failure.

    Units: Binary (YES/NO)

  2. Feasibility of Combined Endobronchial Blood Patch and Spiration Valve Procedure

    Time frame: From enrollment to end of procedure.

    Defined as the successful completion of the combined autologous endobronchial blood patch and Spiration Valve procedure.

    Units: Binary (Yes/No - Procedure Completed as Intended)

Secondary outcomes

  1. Change in Air Leak Severity Based on Cerfolio Classification

    Time frame: From enrollment to end of observational period at 12 months post-intervention as per standard procedure

    This refers to the variation or progression in postoperative pulmonary air leaks, categorized based on the Cerfolio classification system. Units: Change in Cerfolio Grade (e.g., Grade 4 to Grade 2)

  2. Time to Air Leak Resolution

    Time frame: From enrollment to end of observational period at 12 months post-intervention as per standard procedure.

    Duration from the onset of a postoperative air leak to its complete cessation. Units: Days

  3. Change in Chest Tube Suction Requirement

    Time frame: From enrollment to end of observational period at 12 months post-intervention as per standard procedure

    This denotes the alteration in the level or need for suction applied to a chest drainage system over time. Units: cmH₂O

  4. Time to Chest Tube Removal

    Time frame: From enrollment to end of observational period at 12 months post-intervention as per standard procedure

    Duration from intervention to successful removal of the chest tube, indicating resolution of the persistent air leak and adequate lung re-expansion. Units: Days

  5. Subsequent Interventions Required Following Blood Patch and Valve Treatment

    Time frame: From enrollment to end of observational period at 12 months post-intervention as per standard procedure

    Incidence and nature of additional therapeutic procedures required to manage persistent air leaks following the initial combined blood patch and valve intervention. Units: Number of participants requiring ≥1 additional intervention

  6. Incidence of Respiratory Infections Following Combined Blood Patch and Spiration Valve Application

    Time frame: From enrollment to the end of the observational period at 12 months post-intervention.

    This outcome will specifically evaluate the number of participants who develop respiratory infections following the intervention. Respiratory infections of interest include post-obstructive pneumonia and other clinically documented respiratory infections potentially related to the procedure.

    Units: Binary (YES/NO)

Study contacts

Contact information is provided by the study sponsor or research team.

Christine Conley, MD

CONTACT

[email protected]

Jason Beattie, MD

CONTACT

[email protected]

3105298266

Sponsors and collaborators

Lead sponsor

Beth Israel Deaconess Medical Center

Other

Registry information

Official study title

PATCHVALVE Trial: A Prospective Evaluation of Blood Patch and Endobronchial Valves for Persistent Air Leaks - Pilot Study

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Sep 22, 2025
Registry last updated
Sep 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.